Trial Information

NON-INVASIVE BIOMARKERS FOR EARLY DETECTION OF LUNG CANCERS: ELEMENT 1: NON-RANDOMIZED PHASE II EVALUATION AND VALIDATION IN NEWLY DIAGNOSED LUNG CANCER PATIENTS

The study revolves around specifying the exact signatures and accuracy associated with
discriminating between benign and malignant SPNs for each of the biomarkers in the specific
high risk cohort under the NLST screening protocol. To help identify and quantify these
signatures, we will evaluate specifically the volatile signature in the exhaled breath, the
accuracy of LuCED sputum detection, the profile of tumor markers and the specifications of
auto-antibodies through immunoassays and Orbitrap technology, and the PET/CT in patients
already diagnosed with lung cancer.